Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rajeeva Singh

Showing results (11-20 of 25) with videos related to

Pageof 3
Sort By:
Journal of Pharmaceutical Sciences|June 14, 2024
Insight Into the Degradation Pathways of an AAV9Antonela Rodriguez, Supriya Jalimarada-Shivakumar, Ali Banazadeh, et al.
Annals of Surgical Oncology|July 27, 2007
Targeting of insulin-like growth factor-I receptor with a monoclonal antibody inhibits growth of hepatic metastases from human colon carcinoma in miceTodd W Bauer, Fan Fan, Wenbiao Liu, et al.
Cancer Research|August 28, 2003
An anti-insulin-like growth factor I receptor antibody that is a potent inhibitor of cancer cell proliferationErin K Maloney, Jennifer L McLaughlin, Nancy E Dagdigian, et al.
Pharmaceutical Research|February 20, 2025
In vitro Stability Study of a Panel of Commercial Antibodies at Physiological pH and Temperature as a Guide to Screen Biologic Candidate Molecules for the Potential Risk of In vivo Asparagine Deamidation and Activity LossRicha Garg, Sean McCarthy, Alayna George Thompson, et al.
Molecular Pharmaceutics|October 15, 2019
Optimizing Lysosomal Activation of Antibody-Drug Conjugates (ADCs) by Incorporation of Novel Cleavable Dipeptide LinkersPaulin L Salomon, Emily E Reid, Katie E Archer, et al.
Molecular Cancer Therapeutics|April 24, 2015
IMGN853, a Folate Receptor-α (FRα)-Targeting Antibody-Drug Conjugate, Exhibits Potent Targeted Antitumor Activity against FRα-Expressing TumorsOlga Ab, Kathleen R Whiteman, Laura M Bartle, et al.
Journal of Medicinal Chemistry|April 27, 2011
Synthesis and evaluation of hydrophilic linkers for antibody-maytansinoid conjugatesRobert Y Zhao, Sharon D Wilhelm, Charlene Audette, et al.
Bioconjugate Chemistry|March 24, 2011
Disulfide-linked antibody-maytansinoid conjugates: optimization of in vivo activity by varying the steric hindrance at carbon atoms adjacent to the disulfide linkageBrenda A Kellogg, Lisa Garrett, Yelena Kovtun, et al.
ACS Medicinal Chemistry Letters|August 16, 2019
Synthesis of Highly Potent N-10 Amino-Linked DNA-Alkylating Indolinobenzodiazepine Antibody-Drug Conjugates (ADCs)Katie E Archer, Emily E Reid, Manami Shizuka, et al.
Molecular Cancer Therapeutics|May 25, 2016
A New Class of Antibody-Drug Conjugates with Potent DNA Alkylating ActivityMichael L Miller, Nathan E Fishkin, Wei Li, et al.
Pageof 3

Showing results (11-20 of 25) with videos related to

Sort By:
Pageof 3
Journal of Pharmaceutical Sciences|June 14, 2024
Insight Into the Degradation Pathways of an AAV9Antonela Rodriguez, Supriya Jalimarada-Shivakumar, Ali Banazadeh, et al.
Annals of Surgical Oncology|July 27, 2007
Targeting of insulin-like growth factor-I receptor with a monoclonal antibody inhibits growth of hepatic metastases from human colon carcinoma in miceTodd W Bauer, Fan Fan, Wenbiao Liu, et al.
Cancer Research|August 28, 2003
An anti-insulin-like growth factor I receptor antibody that is a potent inhibitor of cancer cell proliferationErin K Maloney, Jennifer L McLaughlin, Nancy E Dagdigian, et al.
Pharmaceutical Research|February 20, 2025
In vitro Stability Study of a Panel of Commercial Antibodies at Physiological pH and Temperature as a Guide to Screen Biologic Candidate Molecules for the Potential Risk of In vivo Asparagine Deamidation and Activity LossRicha Garg, Sean McCarthy, Alayna George Thompson, et al.
Molecular Pharmaceutics|October 15, 2019
Optimizing Lysosomal Activation of Antibody-Drug Conjugates (ADCs) by Incorporation of Novel Cleavable Dipeptide LinkersPaulin L Salomon, Emily E Reid, Katie E Archer, et al.
Molecular Cancer Therapeutics|April 24, 2015
IMGN853, a Folate Receptor-α (FRα)-Targeting Antibody-Drug Conjugate, Exhibits Potent Targeted Antitumor Activity against FRα-Expressing TumorsOlga Ab, Kathleen R Whiteman, Laura M Bartle, et al.
Journal of Medicinal Chemistry|April 27, 2011
Synthesis and evaluation of hydrophilic linkers for antibody-maytansinoid conjugatesRobert Y Zhao, Sharon D Wilhelm, Charlene Audette, et al.
Bioconjugate Chemistry|March 24, 2011
Disulfide-linked antibody-maytansinoid conjugates: optimization of in vivo activity by varying the steric hindrance at carbon atoms adjacent to the disulfide linkageBrenda A Kellogg, Lisa Garrett, Yelena Kovtun, et al.
ACS Medicinal Chemistry Letters|August 16, 2019
Synthesis of Highly Potent N-10 Amino-Linked DNA-Alkylating Indolinobenzodiazepine Antibody-Drug Conjugates (ADCs)Katie E Archer, Emily E Reid, Manami Shizuka, et al.
Molecular Cancer Therapeutics|May 25, 2016
A New Class of Antibody-Drug Conjugates with Potent DNA Alkylating ActivityMichael L Miller, Nathan E Fishkin, Wei Li, et al.
Pageof 3